Breaking News

GBG & Yale Partner for Drug Discovery

Drug discovery services from "target validation" to "lead optimization" for the awardees of the Blavatnik Fund for Innovation

Genesis Biotechnology Group (GBG) and its CRO arm, Genesis Drug Discovery & Development (GD3),  announced that it has entered into a partnership with Yale University to offer an integrated portfolio of drug discovery services from “target validation” to “lead optimization” to the awardees of the Blavatnik Fund for Innovation.    The partnership is a part of GD3‘s efforts to offer early drug discovery-based services to Yale’s researchers, allowing t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters